Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions. Specifically, these include a psychedelic compound derived from mushrooms, aimed at treating post-traumatic stress disorder and depression; an innovative cannabinoid and tree bark-sourced psychedelic intended to combat addiction; and three additional cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. Established in 2014 and headquartered in New York, New York, the company was previously named Gridiron BioNutrients, Inc. before adopting its current moniker, Innovation1 Biotech Inc., in March 2022.
—
Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions. Specifically, these include a psychedelic compound derived from mushrooms, aimed at treating post-traumatic stress disorder and depression; an innovative cannabinoid and tree bark-sourced psychedelic intended to combat addiction; and three additional cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. Established in 2014 and headquartered in New York, New York, the company was previously named Gridiron BioNutrients, Inc. before adopting its current moniker, Innovation1 Biotech Inc., in March 2022.
—
Daily adjusted close
Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions. Specifically, these include a psychedelic compound derived from mushrooms, aimed at treating post-traumatic stress disorder and depression; an innovative cannabinoid and tree bark-sourced psychedelic intended to combat addiction; and three additional cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. Established in 2014 and headquartered in New York, New York, the company was previously named Gridiron BioNutrients, Inc. before adopting its current moniker, Innovation1 Biotech Inc., in March 2022.